---
title: "Cagrilintide Deep Research Review"
slug: "cagrilintide"
type: "research"
url: "https://peptidesciencethailand.com/research/cagrilintide"
lastReviewed: "2026-03-13"
overallScore: "3/5"
verdict: "Clinically demonstrated weight loss drug candidate; not approved; combination data strongest"
description: "How much weight does Cagrilintide actually drop? Phase 2/3 data, CagriSema combo results, side-effect rates — graded vs semaglutide and tirzepatide."
---
# Cagrilintide — Deep Research Review

**Full name:** Cagrilintide (long-acting amylin analogue)  
**Sequence:** Lipidated amylin analogue  
**Molecular weight:** ~4000 Da (acylated peptide)  
**Overall evidence score:** 3/5  
**Verdict:** Clinically demonstrated weight loss drug candidate; not approved; combination data strongest

## Executive Summary

Cagrilintide is a long-acting amylin analogue (dual amylin/calcitonin receptor agonist) engineered for once-weekly subcutaneous dosing. The peer-reviewed evidence base supports one core claim with confidence: it reduces energy intake and produces clinically meaningful weight loss in humans. In the best-described monotherapy trial (a 26-week phase 2 dose-finding RCT, n=706), weekly cagrilintide produced ~6.0%–10.8% mean weight loss (dose-dependent) versus ~3.0% with placebo, with gastrointestinal adverse events common. The most dramatic results come from combination with semaglutide (CagriSema): in REDEFINE 1 (phase 3a; n=3417), CagriSema achieved ~20.4% mean weight loss at 68 weeks versus ~3.0% with placebo, with GI adverse events in ~79.6% of the active group. Cagrilintide is not FDA-approved; the FDA explicitly states it cannot be used in compounding and has not been found safe and effective for any condition. Any cagrilintide sold as a research peptide for self-use is outside regulated medicine.

## Editorial Position

Cagrilintide is a credible, satiety-pathway anti-obesity drug candidate with meaningful monotherapy weight loss and stronger effects when combined with semaglutide. The evidence is unusually trial-heavy for an unapproved compound. The limiting factor is not whether it works; it is regulatory status, long-term safety data, and the gap between trial conditions and unregulated self-use.

## What It Is

Cagrilintide is a stable, lipidated, long-acting analogue of the pancreatic hormone amylin, designed for once-weekly subcutaneous injection. Amylin is co-secreted with insulin and pharmacologically reduces meal size, appetite, and slows gastric emptying via central and peripheral pathways. At the receptor level, amylin receptors are heterodimers built from the calcitonin receptor (CTR) plus RAMP1/2/3, creating AMY receptor subtypes. Cryo-EM structural work has confirmed how cagrilintide engages both AMY receptors and CTR, supporting its classification as a dual amylin/calcitonin receptor agonist. The protracted exposure profile is plausibly driven by reversible albumin binding, a design strategy also used for other long-acting peptide drugs.

## Mechanisms

### Amylin receptor agonism and satiety signalling

*Verdict:* Well-supported mechanistic basis

Cagrilintide activates AMY receptor subtypes (heterodimers of CTR + RAMP1/2/3), producing satiety signalling that reduces meal size and energy intake. Cryo-EM structural studies have mapped how cagrilintide engages these receptor complexes, providing molecular-level rationale for its appetite-suppressing effects. Animal studies in RAMP1/3 knockout mice confirm dependence on AMY receptor subtypes for the weight-lowering phenotype.

### Long-acting pharmacokinetic design

*Verdict:* Demonstrated in human PK studies

Cagrilintide was engineered with lipidation and sequence modifications to overcome native amylin's short half-life and amyloid fibril formation tendency. Human PK data from a phase 1b trial show a half-life of ~159–195 hours (roughly 6.5–8 days), with median tmax of ~24–72 hours, supporting once-weekly dosing. Exposure increased with dose and did not meaningfully alter semaglutide exposure when co-administered.

### Energy expenditure preservation (combination only)

*Verdict:* Preclinical signal, not proven in humans

A preclinical study in rats tested CagriSema and found weight loss driven primarily by reduced energy intake, but with an additional effect described as blunting metabolic adaptation (relative preservation of energy expenditure compared with pair-fed controls).

## Animal Studies

| Domain | Species | Dose | Outcome | Limitation |
| --- | --- | --- | --- | --- |
| Weight loss / receptor dependency | Mouse (high-fat diet; RAMP1/3 KO) | 3 nmol/kg subcutaneous daily (3 weeks) | Weight loss and early food-intake reduction in wild-type mice; effects altered in RAMP1/3 knockout animals, supporting AMY receptor dependence | Rodent dosing and neurobiology do not map cleanly onto human chronic obesity; short duration. |
| Energy balance (CagriSema combination) | Rat | Combination regimen (details in paper) | Weight loss attributed mainly to reduced energy intake, with additional effect on energy expenditure vs pair-fed controls | Combination product, not cagrilintide alone; translation of energy-expenditure findings to humans is uncertain. |

## Human Studies

### Phase 2 dose-finding monotherapy RCT

**Type:** 26-week randomised, blinded phase 2 trial  
**Participants:** 706 adults without diabetes  
**Dose:** Weekly subcutaneous cagrilintide 0.3–4.5 mg; placebo and liraglutide 3.0 mg comparator arms  
**Outcome:** Mean weight loss ~6.0%–10.8% (dose-dependent) vs ~3.0% placebo; highest dose (4.5 mg) exceeded liraglutide (10.8% vs 9.0%); ~10% discontinued, mostly due to AEs; GI AEs common (nausea up to ~47%)  
**Limitations:** 26 weeks only; lifestyle co-interventions; long-term outcomes unknown; not powered for rare adverse events.

### Phase 1b cagrilintide + semaglutide combination

**Type:** 20-week phase 1b trial  
**Participants:** ~96 adults with overweight/obesity  
**Dose:** Multiple cagrilintide doses + semaglutide 2.4 mg weekly  
**Outcome:** Greater mean weight loss in combination cohorts (~15.7%–17.1% at week 20) vs semaglutide+placebo (~9.8%); PK confirmed weekly dosing suitability  
**Limitations:** Small cohorts; short duration; not powered for rare AEs. Exactly the kind of data inflated into guaranteed 15–20% loss claims online.

### Phase 2 CagriSema in type 2 diabetes

**Type:** 32-week randomised phase 2 trial  
**Participants:** 92 adults with type 2 diabetes  
**Dose:** CagriSema 2.4 mg/2.4 mg vs semaglutide alone vs cagrilintide alone, weekly subcutaneous  
**Outcome:** Weight: −15.6% (combo) vs −5.1% (semaglutide) vs −8.1% (cagrilintide); HbA1c: −2.2pp (combo) vs −1.8pp (semaglutide) vs −0.9pp (cagrilintide); no level 2/3 hypoglycaemia  
**Limitations:** Small sample; limited duration; HbA1c advantage of combo over semaglutide did not meet conventional significance thresholds; outcomes trial absent.

### REDEFINE 1: Phase 3a in obesity without diabetes

**Type:** 68-week phase 3a randomised trial  
**Participants:** 3417 adults without diabetes  
**Dose:** CagriSema 2.4 mg/2.4 mg weekly subcutaneous; included cagrilintide-only and semaglutide-only comparator arms  
**Outcome:** Mean weight loss: ~20.4% (CagriSema) vs ~14.9% (semaglutide) vs ~11.5% (cagrilintide) vs ~3.0% (placebo); GI AEs in 79.6% active vs 39.9% placebo  
**Limitations:** Long-term beyond 68 weeks, rare events, and durability still uncertain; full adherence vs real-world gaps matter. Cagrilintide monotherapy less potent than semaglutide at these doses.

### REDEFINE 2: Phase 3a in type 2 diabetes

**Type:** 68-week phase 3a randomised trial  
**Participants:** 1206 adults with type 2 diabetes  
**Dose:** CagriSema 2.4 mg/2.4 mg weekly subcutaneous  
**Outcome:** Weight: −13.7% vs −3.4% placebo; HbA1c ≤6.5%: 73.5% vs 15.9%; GI AEs in 72.5% active vs 34.4% placebo  
**Limitations:** Same durability and rare-event limits as REDEFINE 1; background diabetes medications complicate comparisons; combination product results, not monotherapy.

## Hype vs Evidence

| Claim | Social Media Implies | Evidence Supports | Verdict |
| --- | --- | --- | --- |
| Cagrilintide alone causes ~20%+ weight loss | Monotherapy produces dramatic weight loss comparable to CagriSema | Cagrilintide monotherapy showed ~6%–10.8% mean loss at 26 weeks in phase 2; larger ~20% figures are from cagrilintide+semaglutide combination in phase 3. REDEFINE 1 showed ~11.5% for cagrilintide alone vs ~20.4% for CagriSema. | Misleading (confuses monotherapy with combination) |
| It's basically CagriSema in a vial | Buying cagrilintide alone gives you CagriSema results | CagriSema is a fixed combination regimen in trials; effects differ materially from cagrilintide alone. Weight loss is substantially greater with the combination. | False framing |
| No nausea / easy to tolerate | Minimal side effects compared to GLP-1 drugs | GI adverse events are common across all trials: nausea up to ~47% in some dose groups (phase 2); 79.6% GI AEs in REDEFINE 1 active arm; 72.5% in REDEFINE 2. | False |
| It resets metabolism and prevents weight rebound | Preserves energy expenditure; prevents metabolic adaptation | Rat data suggest blunting of metabolic adaptation for the combination product only; human translation is unproven, and this is not established for cagrilintide monotherapy. | Overhyped (preclinical to clinical leap) |
| It improves diabetes directly / regenerates the pancreas | Direct diabetes treatment with regenerative properties | In T2D phase 2, cagrilintide alone reduced HbA1c modestly (−0.9pp); combination improved HbA1c more than cagrilintide and not clearly more than semaglutide in the primary comparison; no evidence of pancreatic regeneration. | Overstated |
| It reduces heart attacks and strokes | Cardiovascular protection proven | Blood pressure and inflammation markers improve in combination trial analyses; hard cardiovascular outcomes require dedicated outcomes trials which are ongoing or have insufficient publicly conclusive data. | Not demonstrated |
| Compounded cagrilintide is a normal, legal option | Available through standard compounding like other peptides | FDA states cagrilintide cannot be used in compounding and is not an FDA-approved active ingredient; FDA has issued warning letters to vendors marketing such products for human use. | False and high-risk |

## Evidence Ratings

| Domain | Score | Rationale |
| --- | --- | --- |
| Weight loss (monotherapy) | 3/5 | Phase 2 RCT shows dose-dependent ~6%–10.8% loss at 26 weeks; REDEFINE 1 comparator arm shows ~11.5% at 68 weeks. Meaningful but moderate evidence base as a standalone agent. |
| Weight loss (combo with semaglutide) | 4/5 | Large phase 3 RCTs (REDEFINE 1 and 2) show ~20.4% and ~13.7% weight loss at 68 weeks with consistent findings across populations. Strong, well-controlled trial evidence. |
| Glycaemic control (T2D) | 3/5 | Phase 2 RCT shows clinically relevant HbA1c reductions; phase 3 shows improved HbA1c targets. But comparisons vs semaglutide were not clearly superior, and long-term diabetes outcomes beyond glycaemic markers remain unproven for cagrilintide as a distinct contributor. |
| Cardiovascular outcomes | 1/5 | Blood pressure reductions reported in REDEFINE-related analyses (risk-factor outcomes in combination context), but no completed publicly conclusive CV outcomes data establishing event reduction. |
| Safety/tolerability | 3/5 | Common AEs (GI) well characterised across trials up to ~68 weeks; discontinuation rates ~6–8% in phase 3. Rare/long-term harms remain uncertain without post-marketing data. |
| Pharmacokinetics | 3/5 | Human PK described in phase 1b trial: half-life ~159–195 hours, tmax 24–72 hours, supporting weekly dosing. Dose-proportional exposure confirmed. |

## Safety & Regulatory

### Pharmacokinetics

Human pharmacokinetics are best characterised from a phase 1b trial of cagrilintide co-administered with semaglutide. The reported half-life across doses is ~159–195 hours (roughly 6.5–8 days), with median tmax of ~24–72 hours. Exposure increased with dose and did not meaningfully alter semaglutide exposure. This supports practical weekly dosing but also implies that adverse effects and dosing errors (especially outside trials) could persist for days.

### Safety Statement

Across phase 1–3 studies, the dominant safety signal is gastrointestinal intolerance: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, typically described as mostly mild-to-moderate and often concentrated around dose escalation. In the phase 2 monotherapy trial, nausea was reported in up to ~47% in some dose groups. In phase 3, GI AEs were very common: ~79.6% (REDEFINE 1) and ~72.5% (REDEFINE 2). Discontinuation due to adverse events was ~6% vs 3.7% (active vs placebo) in REDEFINE 1 and ~8.4% vs 3% in REDEFINE 2. Rare and long-term harms remain uncertain because there is no post-approval pharmacovigilance base.

### Regulatory Points

**U.S. FDA — Not approved; cannot be compounded**

Cagrilintide is not an FDA-approved active ingredient. The FDA explicitly states it has not been found safe and effective for any condition and cannot be used in compounding under federal law. The FDA has issued warning letters to vendors marketing cagrilintide products for human use.

Source: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

**FDA Enforcement — Warning letters issued**

The FDA has taken enforcement action against companies marketing unapproved cagrilintide-containing products, including warning letters citing violations of federal law regarding unapproved new drugs.

Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024

**EMA — Paediatric investigation plans filed (not marketing authorisation)**

The EMA has published paediatric investigation plan decisions for the cagrilintide/semaglutide combination, indicating regulatory engagement in development but this is not a marketing authorisation.

Source: https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003059-pip01-21

## Open Questions / Unknowns

- No post-marketing safety data exist because cagrilintide is not approved anywhere. Rare adverse events cannot be characterised from trial data alone.
- Long-term weight maintenance beyond 68 weeks is not established; durability of weight loss after discontinuation is unknown.
- Cardiovascular outcomes data (hard events like heart attacks and strokes) are absent; development programmes exist but have not reported conclusive results.
- The contribution of cagrilintide versus semaglutide in the CagriSema combination for glycaemic control remains uncertain; the HbA1c advantage did not reach conventional significance in the phase 2 comparison.
- Energy expenditure preservation (metabolic reset) is a preclinical observation in rats for the combination product only; human relevance is unproven.
- Quality, purity, and dosing accuracy of grey-market research peptide cagrilintide products are unknown and unregulated; the FDA has flagged this as a specific risk area.

## Frequently Asked Questions

### What is cagrilintide?

Cagrilintide is a long-acting amylin analogue (dual amylin/calcitonin receptor agonist) designed for once-weekly subcutaneous injection. It works by activating amylin receptor subtypes to reduce appetite and energy intake. It is currently in clinical development and is not approved by the FDA or any major regulatory body for any indication.

### How much weight can you lose with cagrilintide?

In a 26-week phase 2 trial (n=706), cagrilintide monotherapy produced ~6.0%–10.8% mean weight loss depending on dose, versus ~3.0% with placebo. In the REDEFINE 1 phase 3 trial, cagrilintide alone achieved ~11.5% weight loss at 68 weeks. The larger ~20% figures often cited online come from the CagriSema combination (cagrilintide plus semaglutide), not cagrilintide alone.

### Is cagrilintide FDA approved?

No. As of 2026, cagrilintide is not approved by the FDA or any major regulatory body. The FDA explicitly states it has not been found safe and effective for any condition. Additionally, cagrilintide cannot be legally used in compounding under federal law, and the FDA has issued warning letters to vendors marketing cagrilintide products for human use.

### What are cagrilintide side effects?

The dominant side effects across clinical trials are gastrointestinal: nausea (up to ~47% in some dose groups), vomiting, diarrhoea, constipation, and abdominal discomfort. These are typically mild-to-moderate and concentrated around dose escalation. In phase 3 trials, GI adverse events occurred in ~72–80% of active treatment groups. Discontinuation due to adverse events was ~6–8% in phase 3 studies.

### What is CagriSema?

CagriSema is a fixed combination of cagrilintide (an amylin analogue) plus semaglutide (a GLP-1 receptor agonist) given as a once-weekly subcutaneous injection. In the REDEFINE 1 phase 3 trial, CagriSema achieved ~20.4% mean weight loss at 68 weeks. CagriSema is a combination product. Its results cannot be attributed to cagrilintide alone.

### Cagrilintide vs semaglutide: which is better for weight loss?

In the REDEFINE 1 trial, which included direct comparison arms, semaglutide alone achieved ~14.9% weight loss versus ~11.5% for cagrilintide alone at 68 weeks. The combination of both (CagriSema) achieved ~20.4%. Cagrilintide is meaningful as a weight loss agent but appears less potent than semaglutide at the tested doses. The two drugs work through different receptor systems (amylin vs GLP-1) and appear complementary.

### Can you buy cagrilintide as a research peptide?

Cagrilintide is sold by some online vendors as a research peptide, but this is outside regulated medicine. The FDA explicitly warns that cagrilintide cannot be used in compounding and has issued warning letters to companies marketing such products. Products sold outside regulated systems carry unknown quality, purity, and dosing accuracy risks.

### Does cagrilintide protect against heart disease?

There is no completed, publicly conclusive cardiovascular outcomes data for cagrilintide or CagriSema establishing that it reduces heart attacks or strokes. Blood pressure and some risk-factor improvements have been reported in trial analyses, but these are surrogate markers, not hard event outcomes. Dedicated cardiovascular outcomes trials are in development.

## References

1. **Phase 2 dose-finding monotherapy trial in adults without diabetes** — The Lancet — 2021
   26-week randomised, blinded phase 2 trial (n=706) of weekly cagrilintide 0.3–4.5 mg showing dose-dependent weight loss of ~6.0%–10.8% vs ~3.0% placebo
   https://pubmed.ncbi.nlm.nih.gov/34798060/
2. **Phase 1b cagrilintide + semaglutide PK and weight loss** — The Lancet — 2021
   20-week phase 1b trial testing multiple cagrilintide doses with semaglutide 2.4 mg; half-life ~159–195 hours; combination weight loss ~15.7%–17.1%
   https://pubmed.ncbi.nlm.nih.gov/33894838/
3. **Phase 2 CagriSema vs components in type 2 diabetes** — The Lancet — 2023
   32-week phase 2 RCT (n=92) comparing CagriSema 2.4/2.4 mg vs semaglutide vs cagrilintide in T2D; weight −15.6% vs −5.1% vs −8.1%
   https://pubmed.ncbi.nlm.nih.gov/37364590/
4. **REDEFINE 1: Phase 3a CagriSema in obesity without diabetes** — New England Journal of Medicine — 2025
   68-week phase 3a trial (n=3417); CagriSema ~20.4% weight loss vs ~3.0% placebo; GI AEs 79.6% vs 39.9%
   https://pubmed.ncbi.nlm.nih.gov/40544433/
5. **REDEFINE 2: Phase 3a CagriSema in type 2 diabetes** — New England Journal of Medicine — 2025
   68-week phase 3a trial (n=1206); CagriSema −13.7% weight loss vs −3.4% placebo; HbA1c ≤6.5% in 73.5% vs 15.9%
   https://pubmed.ncbi.nlm.nih.gov/40544432/
6. **Cryo-EM structure of cagrilintide–AMY receptor complex** — Nature Metabolism — 2025
   Structural study mapping cagrilintide engagement with amylin and calcitonin receptor complexes via cryo-electron microscopy
   https://www.nature.com/articles/s42255-025-01324-8
7. **RAMP1/3 knockout study: AMY receptor dependency for weight loss** — Nature Communications — 2025
   High-fat-diet mouse study showing cagrilintide weight loss depends on AMY receptor subtypes; effects altered in RAMP1/3 knockout animals
   https://pmc.ncbi.nlm.nih.gov/articles/PMC11982234/
8. **CagriSema energy balance study in rats** — Nature Pharmacology — 2025
   Preclinical study showing CagriSema weight loss driven by reduced intake with additional energy expenditure preservation vs pair-fed controls
   https://www.nature.com/articles/s41401-025-01635-2
9. **Medicinal chemistry and design of cagrilintide** — Journal of Medicinal Chemistry — 2021
   Drug design publication describing sequence modifications, lipidation strategy, stability improvements, and reduced fibrillation propensity
   https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565
10. **REDEFINE 1 cardiovascular risk factor analysis** — Published 2025 — 2025
   Analysis of blood pressure and cardiovascular risk factor changes from REDEFINE 1 trial
   https://pubmed.ncbi.nlm.nih.gov/40609154/
11. **Systematic review / meta-analysis of cagrilintide trials** — Published 2025 — 2025
   Comprehensive analysis across cagrilintide clinical trial data
   https://pubmed.ncbi.nlm.nih.gov/41328546/
12. **Phase 2 monotherapy trial registry (NCT03856047)** — ClinicalTrials.gov — 2019
   ClinicalTrials.gov registration for the 26-week phase 2 dose-finding monotherapy trial
   https://clinicaltrials.gov/study/NCT03856047
13. **Phase 1b combination trial registry (NCT03600480)** — ClinicalTrials.gov — 2018
   ClinicalTrials.gov registration for the phase 1b cagrilintide + semaglutide trial
   https://clinicaltrials.gov/study/NCT03600480
14. **FDA warning: unapproved GLP-1-related products** — FDA — 2024
   FDA safety communication explicitly stating cagrilintide is not approved and cannot be used in compounding
   https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
15. **FDA warning letter to cagrilintide vendor** — FDA — 2024
   FDA enforcement action against company marketing unapproved cagrilintide products for human use
   https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024
16. **ADA press release on CagriSema weight loss results** — American Diabetes Association — 2025
   American Diabetes Association summary reporting REDEFINE 1 comparator arm data including monotherapy results
   https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity